Video

Future Perspectives in Renal Cell Carcinoma (RCC)

Author(s):

Thomas Hutson, DO, PharmD

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Image of a man wearing a black suit and tie.
Related Content
Photo credit: Taylor Hill/FilmMagic via Getty Images
January 31st 2025

Dwyane Wade Talks Tumor Removal, Bachelorette Star’s Husband Cancer Diagnosis and More

Spencer Feldman
From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of solid tumor makeup.
January 20th 2025

The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors

Ryan Scott
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Image of kidney.
January 9th 2025

Real-World Data May Support Opdivo Plus Yervoy Efficacy in mRCC

Spencer Feldman
Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.